Contents

Foreword V

Preface IX

1 Molecular Objects and Design Objectives 1
1.1 What is a Molecule? 1
1.2 Simplistic Molecular Representations 2
1.3 The Molecular Surface 3
1.4 Molecular Shape 7
1.5 The Topological Molecular Graph 8
1.6 Molecular Properties and Graph Invariants 11
1.7 The Drug-likeness Concept 14
1.8 Scaffolds, Linkers, and Side-chains 16
1.9 Substructure Similarity and “Privileged Motifs” 19
1.10 Molecules as Strings 23
1.11 Constructing Molecules from Strings 25
1.12 From Elements to Atom Types 27
1.13 Entering the Third Dimension: Automatic Conformer Generation 29
1.14 The “Bioactive” Conformation 32

Literature 33

2 Receptor–Ligand Interaction 35
2.1 The Thermodynamics of Protein–Ligand Interaction 35
2.2 The Entropic Contribution 38
2.3 From Theory to Experiment: $K_i$ and $IC_{50}$ 45
2.4 QSAR: Estimating Quantitative Structure–Activity Relationships 47
2.4.1 Free–Wilson Analysis 49
2.4.2 The Hansch Model 51
2.4.3 3D-QSAR 52
2.5 Types of Receptor–Ligand Interaction 54
2.6 The “Biophore” Concept 58
2.7 Potential Pharmacophoric Points 62
2.8 The Correlation Vector Approach to Pharmacophore Modeling 66
2.9 “Hard Sphere” and “Fuzzy” Pharmacophore Models 68
2.10 Lessons from Automated Ligand Docking and Scoring: What Works and What Does Not 74
2.11 Fits Like a Glove: Alternative Ligand Binding Modes and Induced Fit Effects 77
Literature 84

3 Creating the Design 87
3.1 Why We Need Computer-assisted Molecular Design 87
3.2 The Number of Drug Targets is Limited 89
3.3 Ligand Binding Sites 100
3.4 Ligand-based Design of Compound Libraries 108
3.5 Similar Compounds Do Not Necessarily Interact with Their Target in Similar Ways 111
3.6 The Same Ligand Can Adopt Multiple Binding Modes 113
3.7 GPCRs Represent a Challenging Target Family 114
3.8 Natural Products Are a Source of Inspiration 116
3.9 Transition State Analogs Are Potent Enzyme Inhibitors 119
3.10 New Targets Sometimes Require a New Ligand Design Concept 123
3.11 De novo Design Concepts 124
3.12 Primary and Secondary Constraints in de novo Design 125
Literature 145

4 Virtual Screening Triage 149
4.1 The Drug Discovery Pipeline 150
4.2 High-throughput Screening (HTS): Why Is It Successful? 151
4.3 From Hit to Lead 153
4.4 Rationalizing the Design Process 154
4.5 From High to Low Diversity 156
4.6 Quantifying Diversity is Difficult 160
4.7 From Negative Design to Positive Design 162
4.8 Watch Out for Frequent Hitters! 165
4.9 Shape-matching: A Coarse-grained Filtering Step 167
4.10 The Ultimate Goal: Scaffold-hopping 170
4.11 Assessing Chemotype Diversity in Focused Libraries 171
4.12 It Works! Examples of Successful Scaffold-hops Found by Virtual Screening 172
4.13 Case Studies 178
4.13.1 Design of Kv1.5 Ion Channel Modulators 178
4.13.2 Virtual Screening of a Natural-product-derived Combinatorial Library for Novel 5-Lipoxygenase Inhibitors 183
4.13.3 Scaffold de novo Design for Cannabinoid-1 (CB-1) Receptor Ligands 186
Literature 189